Quarterly Result29 Apr 2026, 08:41 pm
RPG Life Sciences Q4/FY26 Results, ₹24 Dividend, New Director
AI Summary
RPG Life Sciences Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board also recommended a dividend of ₹24 per equity share (300% on a face value of ₹8) for FY 2025-26, pending shareholder approval at the upcoming Annual General Meeting. Additionally, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a five-year term starting April 29, 2026. The company also approved an amendment to its Code of fair disclosure and internal procedures for regulating insider trading.
Key Highlights
- Board approved audited financial results for Q4 and FY2025-26.
- Recommended ₹24 per share dividend (300%) for FY2025-26.
- Dr. Pratit Samdani appointed as Additional Independent Director.
- Amended the code for regulating insider trading by designated persons.
Price Impact
More from RPGLIFE